Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis

被引：4

作者：

Bin Riaz, Irbaz ^{[1
,5
,8
,9
]}

Sipra, Qurat Ul Ain Riaz ^{[2
]}

Naqvi, Syed Arsalan Ahmed ^{[1
]}

He, Huan ^{[3
]}

Siddiqi, Rabbia ^{[4
]}

Islam, Mahnoor ^{[4
]}

Asghar, Noureen ^{[2
]}

Ikram, Waleed ^{[1
]}

Xu, Wenxin ^{[5
]}

Liu, Hongfong ^{[3
]}

Singh, Parminder ^{[1
]}

Ho, Thai Huu ^{[1
]}

Bilen, Mehmet Asim ^{[6
]}

Zakharia, Yousef ^{[7
]}

Bryce, Alan Haruo ^{[1
]}

Hassan, Mohammad ^{[3
]}

机构：

[1] Mayo Clin, Phoenix, AZ USA

[2] Univ Arizona, Tucson, AZ USA

[3] Mayo Clin, Rochester, MN USA

[4] Dow Univ Hlth Sci, Karachi, Pakistan

[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Holden Comprehens Canc Ctr, Iowa City, IA USA

[8] Harvard Med Sch, Mass Gen Brigham, Boston, MA USA

[9] Mayo Clin, 5881 E Mayo Blvd, Phoenix, AZ 85054 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 175卷

关键词：

Renal cell carcinoma; Immunotherapy; Pembrolizumab; Baseline risk; Living evidence; HIGH-RISK; NEPHRECTOMY; SUNITINIB; PEMBROLIZUMAB; SURVIVAL; THERAPY; PLACEBO; GUIDELINES; SORAFENIB; PAZOPANIB;

D O I：

10.1016/j.critrevonc.2022.103706

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To assess comparative effectiveness of adjuvant therapies for renal cell carcinoma and quantify the absolute benefit of adjuvant treatments by clinicopathological risk groups. Methods: This 'living' review was conducted using Living Interactive Evidence (LIvE) synthesis framework. Results: The 'living' results are available on an interactive website. This network meta-analysis, including six RCTs with 7525 participants, showed that pembrolizumab (rank 1) significantly improved disease-free survival and overall survival compared with sunitinib but not when compared to pazopanib, and axitinib. The risk of treatment-related grade 3 or higher adverse events was increased with pembrolizumab as compared to placebo and axitinib but not when compared to sunitinib. The absolute benefit of adjuvant pembrolizumab increases substantially with larger tumor size, nodal positivity and higher Leibovich scores. Conclusion: Current evidence suggests that pembrolizumab delays disease progression compared to sunitinib. A risk-adapted strategy should be used in patients undergoing consideration for treatment with adjuvant pembrolizumab.

引用

页数：10

共 39 条

[1] 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma [J].

Bedke, Jens ;

Albiges, Laurence ;

Capitanio, Umberto ;

Giles, Rachel H. ;

Hora, Milan ;

Lam, Thomas B. ;

Ljungberg, Borje ;

Marconi, Lorenzo ;

Klatte, Tobias ;

Volpe, Alessandro ;

Abu-Ghanem, Yasmin ;

Dabestani, Saeed ;

Fernandez-Pello, Sergio ;

Hofmann, Fabian ;

Kuusk, Teele ;

Tahbaz, Rana ;

Powles, Thomas ;

Bex, Axel .

EUROPEAN UROLOGY, 2022, 81 (02) :134-137

[2] Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma [J].

Bergerot, Cristiane Decat ;

Battle, Dena ;

Philip, Errol J. ;

Bergerot, Paulo Gustavo ;

Msaouel, Pavlos ;

Smith, Allan 'Ben' ;

Bamgboje, Adeola Esther ;

Shuch, Brian ;

Derweesh, Ithaar H. ;

Jonasch, Eric ;

Stern, Adam P. ;

Pal, Sumanta K. ;

Staehler, Michael .

JCO ONCOLOGY PRACTICE, 2020, 16 (11) :743-+

[3] Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis [J].

Bin Riaz, Irbaz ;

Siddiqi, Rabbia ;

Islam, Mahnoor ;

He, Huan ;

Riaz, Anum ;

Asghar, Noureen ;

Naqvi, Syed Arsalan Ahmed ;

Warner, Jeremy L. ;

Murad, Mohammad H. ;

Kohli, Manish .

JCO CLINICAL CANCER INFORMATICS, 2021, 5 :588-599

[4] Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? [J].

Blinman, P. L. ;

Davis, I. D. ;

Martin, A. ;

Troon, S. ;

Sengupta, S. ;

Hovey, E. ;

Coskinas, X. ;

Kaplan, R. ;

Ritchie, A. ;

Meade, A. ;

Eisen, T. ;

Stockler, M. R. .

ANNALS OF ONCOLOGY, 2018, 29 (02) :370-376

[5] GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks [J].

Brignardello-Petersen, Romina ;

Murad, M. Hassan ;

Walter, Stephen D. ;

McLeod, Shelley ;

Carrasco-Labra, Alonso ;

Rochwerg, Bram ;

Schunemann, Holger J. ;

Tomlinson, George ;

Guyatt, Gordon H. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2019, 105 :60-67

[6] Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis [J].

Brignardello-Petersen, Romina ;

Bonner, Ashley ;

Alexander, Paul E. ;

Siemieniuk, Reed A. ;

Furukawa, Toshi A. ;

Rochwerg, Bram ;

Hazlewood, Glen S. ;

Alhazzani, Waleed ;

Mustafa, Reem A. ;

Murad, M. Hassan ;

Puhan, Milo A. ;

Schunemann, Holger J. ;

Guyatt, Gordon H. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2018, 93 :36-44

[7] Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project) [J].

Brookman-May, Sabine ;

May, Matthias ;

Shariat, Shahrokh F. ;

Xylinas, Evanguelos ;

Stief, Christian ;

Zigeuner, Richard ;

Chromecki, Thomas ;

Burger, Maximilian ;

Wieland, Wolf F. ;

Cindolo, Luca ;

Schips, Luigi ;

De Cobelli, Ottavio ;

Rocco, Bernardo ;

De Nunzio, Cosimo ;

Feciche, Bogdan ;

Truss, Michael ;

Gilfrich, Christian ;

Pahernik, Sascha ;

Hohenfellner, Markus ;

Zastrow, Stefan ;

Wirth, Manfred P. ;

Novara, Giacomo ;

Carini, Marco ;

Minervini, Andrea ;

Simeone, Claudio ;

Antonelli, Alessandro ;

Mirone, Vincenzo ;

Longo, Nicola ;

Simonato, Alchiede ;

Carmignani, Giorgio ;

Ficarra, Vincenzo .

EUROPEAN UROLOGY, 2013, 64 (03) :472-477

[8] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Tomczak, P. ;

Park, S. H. ;

Venugopal, B. ;

Ferguson, T. ;

Chang, Y. -H. ;

Hajek, J. ;

Symeonides, S. N. ;

Lee, J. L. ;

Sarwar, N. ;

Thiery-Vuillemin, A. ;

Gross-Goupil, M. ;

Mahave, M. ;

Haas, N. B. ;

Sawrycki, P. ;

Gurney, H. ;

Chevreau, C. ;

Melichar, B. ;

Kopyltsov, E. ;

Alva, A. ;

Burke, J. M. ;

Doshi, G. ;

Topart, D. ;

Oudard, S. ;

Hammers, H. ;

Kitamura, H. ;

Bedke, J. ;

Perini, R. F. ;

Zhang, P. ;

Imai, K. ;

Willemann-Rogerio, J. ;

Quinn, D. I. ;

Powles, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :683-694

[9] Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. [J].

Choueiri, Toni K. ;

Tomczak, Piotr ;

Park, Se Hoon ;

Venugopal, Balaji ;

Ferguson, Tom ;

Symeonides, Stefan N. ;

Hajek, Jaroslav ;

Chang, Yen-Hwa ;

Lee, Jae-Lyun ;

Sarwar, Naveed ;

Thiery-Vuillemin, Antoine ;

Gross-Goupil, Marine ;

Mahave, Mauricio ;

Haas, Naomi B. ;

Sawrycki, Piotr ;

Xu, Lei ;

Imai, Kentaro ;

Willemann-Rogerio, Jacqueline ;

Quinn, David I. ;

Powles, Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

[10] Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation [J].

Correa, Andres F. ;

Jegede, Opeyemi ;

Haas, Naomi B. ;

Flaherty, Keith T. ;

Pins, Michael R. ;

Messing, Edward M. ;

Manola, Judith ;

Wood, Christopher G. ;

Kane, Christopher J. ;

Jewett, Michael A. S. ;

Dutcher, Janice P. ;

DiPaola, Robert S. ;

Carducci, Michael A. ;

Uzzo, Robert G. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) :2062-+

← 1 2 3 4 →